Are you Dr. Dominy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 29 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1001 Potrero Ave
Rm 7M
San Francisco, CA 94110Phone+1 415-206-5612Fax+1 415-206-8942
Summary
- Dr. Stephen Dominy, MD is a board certified psychiatrist in San Francisco, California. He is currently licensed to practice medicine in California and Ohio. He is an Associate Professor at UCSF School of Medicine.
Education & Training
- University of California (San Francisco)Residency, Psychiatry, 1995 - 1999
- Wright State University Boonshoft School of MedicineClass of 1995
Certifications & Licensure
- CA State Medical License 1997 - 2026
- OH State Medical License 1979 - 1995
- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 1008 citationsPorphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitorsStephen S. Dominy, Casey C. Lynch, Florian Ermini, Malgorzata Benedyk, Agata Marczyk
Science Advances. 2019-01-01 - 52 citationsAlzheimer's Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains.Ursula Haditsch, Theresa Roth, Leo Rodriguez, Sandy Hancock, Thomas E. Cecere
Journal of Alzheimer's Disease. 2020-01-01 - 13 citationsTreatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388.Shirin Arastu-Kapur, Mai Nguyen, Debasish Raha, Florian Ermini, Ursula Haditsch
Pharmacology Research & Perspectives. 2020-02-01
Press Mentions
- Cortexyme to Present New Data at AAIC 2021July 22nd, 2021
- Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data PresentationMarch 8th, 2021
- Pfizer, Verily-Backed Alzheimer's Biotech Cortexyme Hit by FDA Partial Hold over Liver ToxicityFebruary 16th, 2021
- Join now to see all